The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 1184069)

Published in BMC Gastroenterol on June 21, 2005

Authors

Niels Teich1, Jörg Kleeff, Herbert Lochs, Joachim Mössner, Volker Keim, Helmut Friess, Johann Ockenga

Author Affiliations

1: Universität Leipzig, Medizinische Klinik und Poliklinik II, Leipzig, Germany. niels.teich@medizin.uni-leipzig.de

Articles cited by this

Characterization of a cancer cachectic factor. Nature (1996) 2.46

Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29

Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut (2002) 2.21

Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer (1997) 1.95

Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut (2003) 1.62

Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer (1997) 1.52

Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res (2001) 1.47

A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A (2003) 1.41

Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer (2001) 1.18

Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg (2000) 1.10

The 'cancer cachectic factor'. Support Care Cancer (2002) 1.06

Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer (2001) 1.03

Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas (1994) 0.91

[Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. Z Gastroenterol (2002) 0.88

Articles by these authors

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34

Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42

Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65

Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol (2005) 5.62

Cachexia: a new definition. Clin Nutr (2008) 5.49

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13

Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med (2009) 4.11

Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93

Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology (2007) 3.73

Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet (2011) 3.54

Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16

Prognostic impact of disease-related malnutrition. Clin Nutr (2007) 3.14

Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg (2003) 3.12

Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg (2011) 2.92

Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59

Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg (2007) 2.51

Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48

Adherent biofilms in bacterial vaginosis. Obstet Gynecol (2005) 2.31

Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27

Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg (2008) 2.22

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21

Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology (2007) 2.15

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14

Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10

Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08

StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07

Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int (2011) 2.06

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol (2008) 2.05

An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol (2007) 2.04

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut (2011) 1.96

Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther (2008) 1.95

Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol (2005) 1.93

The German hospital malnutrition study. Clin Nutr (2006) 1.93

A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90

Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol (2009) 1.88

Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology (2003) 1.86

Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85

Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85

Chronic pancreatitis--definition, etiology, investigation and treatment. Dtsch Arztebl Int (2013) 1.82

Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82

Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut (2006) 1.81

Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat (2006) 1.80

CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? Gut (2012) 1.77

From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75

European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis (2013) 1.75

Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res (2005) 1.74

Combined laparoscopic-endoscopic resections of colorectal polyps: 10-year experience and follow-up. Surg Endosc (2009) 1.74

Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73

Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol (2011) 1.72

Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology (2008) 1.68

Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 1.67

Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (2013) 1.62

Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008) 1.62

Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology (2012) 1.61

Invasion and metastasis in pancreatic cancer. Mol Cancer (2003) 1.61

Overlap syndrome of autoimmune pancreatitis and cholangitis associated with secondary Sjögren's syndrome. Eur J Gastroenterol Hepatol (2004) 1.61

Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg (2007) 1.60

Renal cancer cell metastasis into the pancreas: a single-center experience and overview of the literature. Pancreas (2005) 1.58

Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc (2003) 1.57

Duodenum-preserving pancreatic head resection--a randomized controlled trial comparing the original Beger procedure with the Berne modification (ISRCTN No. 50638764). Surgery (2008) 1.55

Complications of pancreatic surgery. HPB (Oxford) (2005) 1.54

Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol (2003) 1.54

Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg (2013) 1.53

Is there still a role for total pancreatectomy? Ann Surg (2007) 1.52

Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia (2009) 1.52

Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer (2005) 1.51

Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51

Management of early hemorrhage from pancreatic anastomoses after pancreaticoduodenectomy. Dig Surg (2006) 1.51

Colorectal cancer surgery remains effective with rising patient age. Int J Colorectal Dis (2014) 1.49

Pancreatic cancer: from bench to 5-year survival. Pancreas (2006) 1.49

Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol (2007) 1.48